lidocain/tetracain eurocept 70 mg/70 mg gyógyszeres tapasz
eurocept international bv - lidokain; tetracaint -
faringopront 3 mg/0,2 mg citrom-menta ízesítésű szopogató tabletta
pierre fabre médicament - klórhexidin; tetracaint -
faringopront 3 mg/0,2 mg cukormentes szopogató tabletta
pierre fabre médicament - klórhexidin; tetracaint -
faringopront 3 mg/0,2 mg méz ízesítésű szopogató tabletta
pierre fabre médicament - klórhexidin; tetracaint -
faringopront 3 mg/0,2 mg szopogató tabletta
pierre fabre médicament - klórhexidin; tetracaint -
pliapeel 70 mg/g + 70 mg/g krém
egis gyógyszergyár zrt. - lidokain; tetracaint -
tetracaine 1 pour cent thea, collyre en solution en récipient unidose
laboratoires thea - tétracaïne (chlorhydrate de) 4 mg - collyre - 4 mg - pour un récipient unidose de 0,4 ml > tétracaïne (chlorhydrate de 4 mg - médicaments ophtalmologiques - classe pharmacothérapeutique - code atc : s01ha03tetracaine 1 pour cent thea, collyre en solution contient une substance active, la tétracaïne. cette substance est un anesthésique local capable de pénétrer dans certaines parties de l’œil comme la cornée et la conjonctive.ce médicament est indiqué comme anesthésique local au cours de différentes interventions chirurgicales ou différents examens de l’œil.
tetracaine hydrochloride solution/ drops
paragon bioteck, inc. - tetracaine hydrochloride (unii: 5nf5d4opci) (tetracaine - unii:0619f35cgv) - tetracaine hydrochloride ophthalmic solution usp, 0.5% is indicated for procedures requiring a rapid and short-acting topical ophthalmic anesthetic. tetracaine hydrochloride ophthalmic solution, usp, 0.5% should not be used in patients with a history of hypersensitivity to any component of this preparation. risk summary there are no adequate and well-controlled studies with tetracaine hydrochloride ophthalmic solution usp, 0.5% in pregnant women. animal developmental and reproductive toxicity studies with tetracaine hydrochloride have not been reported in the published literature. risk summary there are no data to assess whether tetracaine hydrochloride ophthalmic solution usp, 0.5% is excreted in human milk or to assess its effects on milk production/excretion. the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for tetracaine hydrochloride ophthalmic solution usp, 0.5% and any potential adverse effects on the breastfed child from tetracaine hydro
tetracaine hydrochloride solution/ drops
oceanside pharmaceuticals - tetracaine hydrochloride (unii: 5nf5d4opci) (tetracaine - unii:0619f35cgv) - tetracaine hydrochloride ophthalmic solution, usp 0.5% is indicated for procedures requiring a rapid and short-acting topical ophthalmic anesthetic. tetracaine hydrochloride ophthalmic solution, usp 0.5% should not be used in patients with a history of hypersensitivity to any component of this preparation. risk summary there are no adequate and well-controlled studies with tetracaine hydrochloride ophthalmic solution, usp 0.5% in pregnant women. animal developmental and reproductive toxicity studies with tetracaine hydrochloride have not been reported in the published literature. risk summary there are no data to assess whether tetracaine hydrochloride ophthalmic solution, usp 0.5% is excreted in human milk or to assess its effects on milk production/excretion. the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for tetracaine hydrochloride ophthalmic solution, usp 0.5% and any potential adverse effects on the breastfed child from tetracaine hydroc
tetracaine hydrochloride solution
nucare pharmaceuticals,inc. - tetracaine hydrochloride (unii: 5nf5d4opci) (tetracaine - unii:0619f35cgv) - tetracaine hydrochloride ophthalmic solution 0.5% is indicated for procedures requiring a rapid and short-acting topical ophthalmic anesthetic. none. risk summary there are no adequate and well-controlled studies with tetracaine hydrochloride ophthalmic solution 0.5% in pregnant women. animal developmental and reproductive toxicity studies with tetracaine hydrochloride have not been reported in the published literature. risk summary there are no data to assess whether tetracaine hydrochloride ophthalmic solution 0.5% is excreted in human milk or to assess its effects on milk production/excretion. the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for tetracaine hydrochloride ophthalmic solution 0.5% and any potential adverse effects on the breastfed child from tetracaine hydrochloride ophthalmic solution 0.5% or from the underlying maternal condition. no human data on the effect of tetracaine hydrochlo